Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q4 2023 Results Conference Call March 18, 2024 4:30 PM ET

Company Participants

Temre Johnson - Senior Director, Investor Relations and Corporate Communications
Mitchell Gold - Executive Chairman and Chief Executive Officer
Stanford Peng - President and Head of Research & Development
Paul Rickey - Chief Financial Officer

Conference Call Participants

Tara Bancroft - TD Cowen
Mike Ulz - Morgan Stanley
Thomas Smith - Leerink Partners
Matt Biegler - Oppenheimer
Joe Pantginis - H.C. Wainwright
Robert Driscoll - Wedbush Securities
Andy Chen - Wolfe Research

Operator

Ladies and gentlemen, welcome to the Alpine Immune Sciences Fourth Quarter 2023 and Full-Year Earnings Call. Currently, all participants are in a listen-only mode. As a reminder, this event is being recorded.

And I would now like to introduce Temre Johnson, Senior Director of Investor Relations and Corporate Communications at Alpine. Ms. Johnson, please go ahead.

Temre Johnson

Thank you, Ravi. Good afternoon, and thank you to everyone for taking the time to join us today. With me on today's call from Alpine are Dr. Mitchell Gold, Executive Chairman and Chief Executive Officer; Dr. Stanford Peng, President and Head of R&D; Paul Rickey, Chief Financial Officer; and Dr. Remy Durand, Chief Business Officer.

Before I turn the call over to Mitch, I'd like to remind you that we'll be making forward-looking statements during today's call. These forward-looking statements represent our views as of today and are based on our current expectations and consequently involve risks and uncertainties. Actual results could differ materially from those anticipated in such forward-looking statements as a result of such risks and uncertainties. I encourage you to refer to the most recent SEC filings regarding the risk factors associated with these statements.

Mitch, please go ahead.

Mitchell Gold

Thank you, Temre, and thank you all of those who are participating in the webcast today. 2023 was a transformational year for Alpine with initial IgA nephropathy data presented at the American Society of Nephrology's Kidney Week suggesting a best-in-class profile of povetacicept, our wholly-owned next-generation dual BAFF/APRIL inhibitor with once-monthly dosing developed using our direct evolution platform.

We are still only in the early stages of exploring the full potential of povetacicept. On the back of strong enthusiasm around ASN, we closed an oversubscribed $150 million equity offering to accelerate multiple development activities.

With our encouraging data set in IgAN, convenient once-monthly dosing regimen, a strong balance sheet, we are rapidly advancing development of POVI as a potentially meaningfully new therapeutic option for patients living with IgAN, lupus, and multiple other autoimmune and inflammatory diseases.